Evidence map›Paper›PMID 33723576›Full record

ArticleBrain : a journal of neurology2021

Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma.

Caty Carrera, Jara Cárcel-Márquez, Natalia Cullell, Nuria Torres-Águila, Elena Muiño, José Castillo, Tomás Sobrino, Francisco Campos, Emilio Rodríguez-Castro, Laia Llucià-Carol and 41 more

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. A potential relationship betweenFrontiers in neurology · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Journal of clinical medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors at 20 institutions in 7 countries.

Caty CarreraNeurovascular Research Laboratory, VHIR, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.
Jara Cárcel-MárquezStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
Natalia CullellStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
Nuria Torres-ÁguilaStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
Elena MuiñoStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
José CastilloClinical Neurosciences Research Laboratory, IDIS, Santiago de Compostela, 15706, Spain.
Tomás SobrinoClinical Neurosciences Research Laboratory, IDIS, Santiago de Compostela, 15706, Spain.
Francisco CamposClinical Neurosciences Research Laboratory, IDIS, Santiago de Compostela, 15706, Spain.
Emilio Rodríguez-CastroDepartment of Neurology, CHUS, Santiago de Compostela, 15706, Spain.
Laia Llucià-CarolStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
Mònica MillánDepartment of Neuroscience, HUGTP, Badalona 08916, Spain.
Lucía Muñoz-NarbonaDepartment of Neuroscience, HUGTP, Badalona 08916, Spain.
Elena López-CancioStroke Unit, HUCA, Oviedo 33011, Spain.
Alejandro BustamanteNeurovascular Research Laboratory, VHIR, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.
Marc RibóStroke Unit, HUVH, Barcelona 08035, Spain.
José Álvarez-SabínDepartment of Neurology, HUVH, UAB, Barcelona 08035, Spain.
Jordi Jiménez-CondeDepartment of Neurology, Neurovascular Research Group, IMIM-Hospital del Mar, Barcelona 08003, Spain.
Jaume RoquerDepartment of Neurology, Neurovascular Research Group, IMIM-Hospital del Mar, Barcelona 08003, Spain.
Eva Giralt-SteinhauerDepartment of Neurology, Neurovascular Research Group, IMIM-Hospital del Mar, Barcelona 08003, Spain.
Carolina Soriano-TárragaDepartment of Neurology, Neurovascular Research Group, IMIM-Hospital del Mar, Barcelona 08003, Spain.
Marina Mola-CaminalDepartment of Neurology, Neurovascular Research Group, IMIM-Hospital del Mar, Barcelona 08003, Spain.
Cristófol Vives-BauzaNeurobiology Laboratory, IdISPa, Mallorca 07120, Spain.
Rosa Díaz NavarroDepartment of Neurology, HUSE, Mallorca 07120, Spain.
Silvia TurDepartment of Neurology, HUSE, Mallorca 07120, Spain.
Victor ObachDepartment of Neurology, Hospital Clínic i Provincial de Barcelona, Barcelona 08036, Spain.
Juan Francisco ArenillasDepartment of Neurology, Hospital Clínico Universitario, University of Valladolid, Valladolid 47003, Spain.
Tomás SeguraDepartment of Neurology, CHUA, Albacete 02006, Spain.
Gemma Serrano-HerasExperimental Research Unit, CHUA, Albacete 02006, Spain.
Joan Martí-FàbregasDepartment of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona 08025, Spain.
Raquel Delgado-MederosDepartment of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona 08025, Spain.
M Mar Freijo-GuerreroNeurovascular Unit, Biocruces Bizkaia Health Research Institute, Bilbao 48903, Spain.
Francisco MonicheDepartment of Neurology, Virgen del Rocío, IBIS, Seville 41023, Spain.ORCID 0000-0001-8613-2909
Juan Antonio CabezasDepartment of Neurology, Virgen del Rocío, IBIS, Seville 41023, Spain.
Mar CastellanosDepartment of Neurology, CHUAC, A Coruña 15006, Spain.
Cristina Gallego-FabregaStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.ORCID 0000-0003-3229-5512
Jonathan González-SanchezStroke Pharmacogenomics and Genetics, Fundació Docència i Recerca Mútua Terrassa, Terrassa 08221, Spain.
Jurek KrupinskySchool of Healthcare Science, Manchester Metropolitan University, Manchester M15 6BH, UK.
Daniel StrbianDepartment of Neurology, Helsinki University Hospital, Helsinki FI-00029, Finland.
Turgut TatlisumakSahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg 41345, Sweden.
Vincent ThijsStroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, VIC 3072, Australia.
Robin LemmensDepartment of Neurology, University Hospitals Leuven, Campus Gasthuisberg, Leuven 3000, Belgium.
Agnieszka SlowikDepartment of Neurology, Jagiellonian University Medical College, Kraków 31-007, Poland.
Johanna PeraDepartment of Neurology, Jagiellonian University Medical College, Kraków 31-007, Poland.
Steven KittnerDepartment of Neurology, University of Maryland School of Medicine and Baltimore, Baltimore, MD 21201-1559, USA.
John ColeDepartment of Neurology, University of Maryland School of Medicine and Baltimore, Baltimore, MD 21201-1559, USA.
Laura HeitschDivision of Emergency Medicine, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Laura IbañezDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Jin-Moo LeeDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Joan MontanerNeurovascular Research Laboratory, VHIR, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.
Israel Fernández-CadenasStroke Pharmacogenomics and Genetics, IIB-Sant Pau, Barcelona 08025, Spain.
Hospital Del Mar · ESWashington University in St. Louis · USInstituto de Investigación Sanitaria de Santiago · ESUniversitat Autònoma de Barcelona · ESUniversity Hospital Mútua de Terrassa · ESHospital de Sant Pau · ESHospital General Universitario de Albacete · ESHospital Municipal de Badalona · ESInstituto de Biomedicina de Sevilla · ESJagiellonian University · PLManchester Metropolitan University · GBUniversity of Maryland, Baltimore · USBioCruces Health research Institute · ESComplexo Hospitalario Universitario A Coruña · ESHelsinki University Hospital · FIHospital Clínic de Barcelona · ESHospital Universitario Central de Asturias · ESSahlgrenska University Hospital · SEThe University of Melbourne · AUUniversidad de Valladolid · ES

Funding

Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D, TAYLOR, SIMEON I. · 2005 to 2019
$17.3M
Genetics of Early-Onset Ischemic Stroke ConsortiumR01NS105150 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI KITTNER, STEVEN J, MITCHELL, BRAXTON D · 2018 to 2022
$3.0M
Genetic Architecture of Acute Human Brain IschemiaR01NS085419 · NINDS · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, LEE, JIN-MOO · 2014 to 2018
$2.8M
GENETICS OF EARLY NEUROLOGICAL INSTABILITY AFTER ISCHEMIC STROKE (GENISIS)K23NS099487 · NINDS · WASHINGTON UNIVERSITY · PI HEITSCH, LAURA · 2017 to 2021
$996k
NIDDK NIH HHS P30 DK072488NINDS NIH HHS K23 NS099487NINDS NIH HHS R01 NS085419NINDS NIH HHS R01 NS105150
6 · The paper itself

Abstract

Haemorrhagic transformation is a complication of recombinant tissue-plasminogen activator treatment. The most severe form, parenchymal haematoma, can result in neurological deterioration, disability, and death. Our objective was to identify single nucleotide variations associated with a risk of parenchymal haematoma following thrombolytic therapy in patients with acute ischaemic stroke. A fixed-effect genome-wide meta-analysis was performed combining two-stage genome-wide association studies (n = 1904). The discovery stage (three cohorts) comprised 1324 ischaemic stroke individuals, 5.4% of whom had a parenchymal haematoma. Genetic variants yielding a P-value < 0.05 1 × 10-5 were analysed in the validation stage (six cohorts), formed by 580 ischaemic stroke patients with 12.1% haemorrhagic events. All participants received recombinant tissue-plasminogen activator; cases were parenchymal haematoma type 1 or 2 as defined by the European Cooperative Acute Stroke Study (ECASS) criteria. Genome-wide significant findings (P < 5 × 10-8) were characterized by in silico functional annotation, gene expression, and DNA regulatory elements. We analysed 7 989 272 single nucleotide polymorphisms and identified a genome-wide association locus on chromosome 20 in the discovery cohort; functional annotation indicated that the ZBTB46 gene was driving the association for chromosome 20. The top single nucleotide polymorphism was rs76484331 in the ZBTB46 gene [P = 2.49 × 10-8; odds ratio (OR): 11.21; 95% confidence interval (CI): 4.82-26.55]. In the replication cohort (n = 580), the rs76484331 polymorphism was associated with parenchymal haematoma (P = 0.01), and the overall association after meta-analysis increased (P = 1.61 × 10-8; OR: 5.84; 95% CI: 3.16-10.76). ZBTB46 codes the zinc finger and BTB domain-containing protein 46 that acts as a transcription factor. In silico studies indicated that ZBTB46 is expressed in brain tissue by neurons and endothelial cells. Moreover, rs76484331 interacts with the promoter sites located at 20q13. In conclusion, we identified single nucleotide variants in the ZBTB46 gene associated with a higher risk of parenchymal haematoma following recombinant tissue-plasminogen activator treatment.

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overCerebral HemorrhageFemaleFibrinolytic AgentsGenome-Wide Association StudyHumansIschemic StrokeMaleMiddle AgedThrombolytic TherapyTissue Plasminogen ActivatorTranscription FactorsTreatment OutcomeFibrinolytic AgentsTissue Plasminogen ActivatorTranscription FactorsZbtb46 protein, humanGWASischaemic strokeparenchymal haematomapharmacogeneticsthrombolysis

Identifiers

PMID33723576
PMCPMC8418348
OpenAlexW3137366382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.